Regulators of hepcidin expression.


Journal

Vitamins and hormones
ISSN: 0083-6729
Titre abrégé: Vitam Horm
Pays: United States
ID NLM: 0413601

Informations de publication

Date de publication:
2019
Historique:
entrez: 26 2 2019
pubmed: 26 2 2019
medline: 6 6 2019
Statut: ppublish

Résumé

Iron, an essential nutrient, is required for many biological processes but is also toxic in excess. The lack of a mechanism to excrete excess iron makes it crucial for the body to regulate the amount of iron absorbed from the diet. This regulation is mediated by the hepatic hormone hepcidin. Hepcidin also controls iron release from macrophages that recycle iron and from hepatocytes that store iron. Hepcidin binds to the only known iron export protein, ferroportin, inducing its internalization and degradation and thus limiting the amount of iron released into the plasma. Important regulators of hepcidin, and therefore of systemic iron homeostasis, include plasma iron concentrations, body iron stores, infection and inflammation, hypoxia and erythropoiesis, and, to a lesser extent, testosterone. Dysregulation of hepcidin production contributes to the pathogenesis of many iron disorders: hepcidin deficiency causes iron overload in hereditary hemochromatosis and non-transfused β-thalassemia, whereas overproduction of hepcidin is associated with iron-restricted anemias seen in patients with chronic inflammatory diseases and inherited iron-refractory iron-deficiency anemia. The present review summarizes our current understanding of the molecular mechanisms and signaling pathways contributing to hepcidin regulation by these factors and highlights the issues that still need clarification.

Identifiants

pubmed: 30798807
pii: S0083-6729(19)30005-6
doi: 10.1016/bs.vh.2019.01.005
pii:
doi:

Substances chimiques

Bone Morphogenetic Proteins 0
Hepcidins 0
Iron E1UOL152H7

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101-129

Informations de copyright

© 2019 Elsevier Inc. All rights reserved.

Auteurs

Marie-Paule Roth (MP)

Institut de Recherche en Santé Digestive (IRSD), Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France. Electronic address: marie-paule.roth@inserm.fr.

Delphine Meynard (D)

Institut de Recherche en Santé Digestive (IRSD), Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France.

Hélène Coppin (H)

Institut de Recherche en Santé Digestive (IRSD), Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH